FilingSEC EDGAR8-K
CervoMed Reports Initial Biomarker Data from Phase 2a Trial in nfvPPA
· SEC accepted
StagePhase 2a
Filing content
CervoMed announced initial 12-week biomarker data from its Phase 2a clinical trial of neflamapimod in nfvPPA, showing a reduction in plasma neurofilament light chain (NfL) levels.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…